Radiopharmaceutical and Radioligand Therapy Patent Landscape and Freedom-to-Operate in 2026
Writen By:
Cypris Research Team
Radioligand therapy has become one of the fastest-growing modalities in oncology, and its patent landscape is distinctive because a radiopharmaceutical is a modular product assembled from independently patentable parts. A radioligand therapy joins a radioactive isotope to a targeting molecule, an antibody, peptide, or small molecule that homes to a tumor marker, through a chelator that holds the isotope and a linker that connects the pieces, and it is delivered under a specific dosing regimen and produced by a specialized, time-critical manufacturing process. Peer-reviewed analyses of the modality describe exactly this layered structure, spanning the radioisotope and its decay-chain radiochemistry and quality control, the chelator, and the targeting vector.¹,²,³ A notable feature of the record is that most patent families in this space disclose the vector, the radiolabel, and the chelator together rather than in isolation, so the layers, while conceptually distinct, are rarely cleanly separated, which is itself a landscape finding. Because these elements can nonetheless be claimed separately and are often held by different owners, freedom-to-operate for a new radioligand therapy is a multi-layer, multi-owner analysis rather than a single clearance.
The commercial and deal environment has raised the stakes across every layer. The approval and rapid uptake of the first marketed radioligand therapies validated the model: Lutathera (lutetium-177 dotatate) was approved in 2017 in the European Union and 2018 in the United States and expanded to pediatric patients aged twelve and older with gastroenteropancreatic neuroendocrine tumors in April 2024,⁴ and Pluvicto (lutetium-177 vipivotide tetraxetan) received initial US approval in 2022.⁵ A wave of multi-billion-dollar acquisitions followed as large pharmaceutical companies, including Bristol Myers Squibb, Eli Lilly, AstraZeneca, and Novartis, bought their way into targeting platforms and, increasingly, into isotope access; Bristol Myers Squibb's all-cash acquisition of RayzeBio, at roughly $4.1 billion in equity value ($62.50 per share), is representative of the scale of the deals.⁶ Because radiopharmaceuticals decay on a clock, the supply and quality control of the isotope, particularly short-lived alpha-emitters, has become a strategic constraint, and it remains a named bottleneck in the peer-reviewed literature.³ The patent picture reflects both the therapy and the infrastructure around it: across the Cypris corpus of more than 500 million patents and scientific papers, the radioligand- and radionuclide-therapy space holds roughly 25,600 de-duplicated families and has grown about 2.8 times from 2015 to 2024, with the United States far in front on geography, followed by Germany, Switzerland, and China, and the most active assignees spanning pharmaceutical companies, imaging and isotope suppliers, and academic medical centers. Because applications publish about eighteen months after filing, the newest chelator, ligand, and manufacturing filings are under-represented (2025 and 2026 counts are partial), so the current frontier is more active than granted-patent counts suggest.
The strategic picture turns on two shifts. First, the field is moving from beta-emitting isotopes toward more potent, shorter-range alpha-emitters such as actinium-225, whose high-energy, short-range emissions can raise tumor cell kill while limiting marrow toxicity.⁷,⁸,⁹ That shift is visible but still early in the patent record: across the Cypris corpus, the beta-emitter slice outweighs the alpha-emitter slice by roughly 1.8 to 1 on an indicative basis, so the field remains beta-dominant even as the alpha share rises quickly. The shift also changes the IP, because the chelators, purification methods, and supply chains for alpha-emitters are distinct and less mature; specialized macrocyclic chelators developed for actinium, and computational chelator-design methods, define much of this layer, and theranostic chelators that pair imaging and therapy add another dimension.¹⁰,¹¹,¹² Second, because a working therapy requires rights across the isotope, the chelator, the ligand, and the manufacturing chain, licensing structure matters as much as claim scope, and newer targeting vectors, such as somatostatin-receptor agonists and antagonists for neuroendocrine tumors, open fresh ligand-layer positions.¹³ Reading the landscape by layer and by owner, and tracking both the patents and the underlying chemistry and nuclear-medicine research, is what separates a workable position from a blocked one.
What creates FTO risk in radioligand therapy
Isotope and isotope-production claims. These cover the radioisotope and the methods to produce, purify, and quality-control it, an increasingly contested layer as alpha-emitter supply becomes a bottleneck.²,³
Chelator and linker claims. These cover the chemistry that holds the isotope and connects it to the targeting molecule, a distinct and heavily engineered layer, especially for alpha-emitters.¹⁰
Targeting ligand claims. These cover the antibody, peptide, or small molecule that directs the therapy to a tumor marker, often the most visible layer and a frequent source of competition.¹³
Combination and regimen claims. These cover pairings with other agents and specific dosing schedules, which can independently block a competing label.
Manufacturing and supply-chain claims. These cover the time-critical production, formulation, and distribution of a decaying product, where practical, hard-to-design-around barriers concentrate.³
How AI-powered landscape and FTO analysis helps
A modular, multi-owner, supply-constrained landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant isotope, chelator, ligand, combination, and manufacturing claims regardless of terminology, attribution that resolves the many owners and the license and acquisition chains to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings, supply agreements, and deals. Because radiopharmaceutical advances appear in scientific and nuclear-medicine literature before they are patented, reading both patents and literature gives earlier warning of where the field is heading.
Where Cypris fits
Cypris runs patent landscape and freedom-to-operate analysis for modular, contested fields such as radioligand therapy across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by layer, isotope, chelator, targeting ligand, combination, and manufacturing, and normalizes owners and their acquisition chains to canonical entities, so a team sees how rights and isotope access are distributed across many parties rather than a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying chemistry and nuclear-medicine research, which is where new chelators, alpha-emitter methods, and ligands emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.
FAQ
Why is freedom-to-operate hard for radioligand therapy? Freedom-to-operate is hard for radioligand therapy because a radiopharmaceutical is assembled from several independently patentable layers, the isotope, the chelator, the targeting ligand, the combination regimen, and the manufacturing and supply chain, often held by different owners. In practice most filings disclose several layers together. FTO is therefore a multi-layer, multi-owner analysis that must also account for isotope access.
Why is isotope supply a strategic issue? Isotope supply is strategic because radiopharmaceuticals decay on a clock, so a therapy is only viable if the isotope can be produced, purified, and delivered on time, and the supply of short-lived alpha-emitters is constrained. The preparation and quality control of actinium-225 in particular remain named bottlenecks in the literature. The isotope-production and purification layer is increasingly patented and contested.
What claim types create FTO risk in radioligand therapy? Five claim types create FTO risk: isotope and isotope-production claims, chelator and linker claims, targeting ligand claims, combination and regimen claims, and manufacturing and supply-chain claims. Each covers a distinct layer and can be held by a different owner. The chelator and isotope-production layers are especially decisive for alpha-emitters.
Why is the shift from beta to alpha emitters important? The shift matters because alpha-emitters are more potent over a shorter range, but their chelators, purification methods, and supply chains are distinct and less mature than those for beta-emitters. In the patent record the field is still beta-dominant, with alpha rising quickly. That immaturity opens white space for developers who solve the chemistry and supply problems.
Where is the white space in radiopharmaceuticals? The white space sits in alpha-emitter chelators and purification, isotope-production methods, novel targeting ligands for markers beyond the most crowded targets, and time-critical manufacturing and distribution. The leading targets and beta-emitter chemistries are comparatively crowded. The higher-value opportunities are in the alpha-emitter and supply layers.
Why does radiopharmaceutical analysis need scientific literature? Radiopharmaceutical analysis needs scientific literature because chelator, isotope, and ligand advances appear in chemistry and nuclear-medicine research before they are patented, so the literature gives the earliest signal. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.
What software helps analyze the radiopharmaceutical patent landscape? Software for the radiopharmaceutical landscape should resolve owners, acquisition chains, and isotope access to canonical entities, cluster the isotope, chelator, ligand, and manufacturing layers, search patents and scientific literature semantically, and monitor deals and new filings continuously. Cypris does this across more than 500 million patents and scientific papers using a proprietary R&D ontology, semantic search, Cypris Q, and Agentic Monitoring.
Which teams need radiopharmaceutical patent landscape and FTO analysis? Radiopharmaceutical patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at radiopharma and oncology companies, isotope producers, and their partners, as well as investors assessing radioligand assets. The modular, supply-constrained, deal-driven landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.
Endnotes
- Andrade, D. B., Chen, S., Lee, S. T., Vallis, K. A., et al. (2024). A meta-analysis and meta-regression of PSMA radioligand therapy utilising lutetium-177 and actinium-225 in metastatic prostate cancer. European Urology. https://doi.org/10.1016/j.eururo.2024.09.020
- Seimbille, Y., de Blois, E., Morgenstern, A., et al. (2025). Ac-225 radiochemistry through the lens of [225Ac]Ac-DOTA-TATE. EJNMMI Radiopharmacy and Chemistry, 10. https://doi.org/10.1186/s41181-025-00332-z
- Duatti, A. (2025). Open problems for the preparation and quality control of Ac-225 radiopharmaceuticals. Current Radiopharmaceuticals. https://doi.org/10.1016/j.craph.2025.100004
- U.S. Food and Drug Administration (2024, April 23). FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years and older with GEP-NETS. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-dotatate-pediatric-patients-12-years-and-older-gep-nets
- U.S. Food and Drug Administration (2022). PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf
- Bristol Myers Squibb (2023). Broadening our oncology capabilities with the acquisition of RayzeBio (Exhibit 99.1), U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/14272/000114036123059406/ny20017436x1_ex99-1.htm
- Bishnoi, K., Panda, A. K., Parida, G. K., & Agrawal, K. (2023). Efficacy and safety of Ac-225 PSMA radioligand therapy in metastatic prostate cancer: a systematic review and meta-analysis. Medical Principles and Practice, 32(3). https://doi.org/10.1159/000531246
- Pini, C., Gelardi, F., Gandaglia, G., et al. (2025). Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer — systematic review and meta-analysis. Theranostics, 15. https://doi.org/10.7150/thno.106574
- Treglia, G., Impériale, A., Paone, G., et al. (2025). Efficacy and safety of radioligand therapy with actinium-225 DOTATATE in neuroendocrine neoplasms: a systematic review and meta-analysis. Medicina, 61(8), 1341. https://doi.org/10.3390/medicina61081341
- Thiele, N. A., Radchenko, V., Ramogida, C. F., Wilson, J. J., et al. (2017). An eighteen-membered macrocyclic ligand for actinium-225 targeted alpha therapy. Angewandte Chemie International Edition, 56(46). https://doi.org/10.1002/anie.201709532
- Stein, B. W., Lilley, L. M., Batista, E. R., et al. (2020). Computer-assisted design of macrocyclic chelators for actinium-225 radiotherapeutics. Inorganic Chemistry, 59(21). https://doi.org/10.1021/acs.inorgchem.0c02432
- Comba, P., Zarschler, K., Stephan, H., et al. (2022). Toward personalized medicine: one chelator for imaging and therapy with lutetium-177 and actinium-225. Journal of the American Chemical Society, 144(41). https://doi.org/10.1021/jacs.2c08438
- Jakobsson, V., Baum, R. P., Greifenstein, L., Zhang, J., et al. (2022). Alpha-PRRT using actinium-225-labeled somatostatin receptor agonists and antagonists. Frontiers in Medicine, 9. https://doi.org/10.3389/fmed.2022.1034315
